TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. Healthy status confirmed by History, Physical Exam and blood work through the CHI Screening Protocol.~ 2. Age 21 years to 45 years~ 3. Able to comprehend the investigational nature of the protocol and provide informed consent~ 4. Must be willing to use effective birth control for one month before, during and for two months after the last vaccination.~EXCLUSION CRITERIA:~1. Severe allergies to eggs or their products, chicken proteins or to any component of the influenza antigen preparation.~2. Recipient of AS03 vaccine at any time in the past~3. Recipient of the seasonal influenza vaccine within the past 3 months.~4. Prior severe reactions to vaccines, including influenza vaccines (e.g. anaphylaxis, angioedema or urticaria)~5. Participation on any blood collection or blood donation procedure during study that will bring the total blood draw \>550ml over 8 weeks~6. Current pregnancy (women of child bearing potential must have a negative serum pregnancy test done on screening within 1 week of protocol accrual)~7. Currently breast-feeding~8. History of Guillain Barre syndrome~9. Acute illness with patient reported temperature of 38 (Infinite)C or greater within 3 days prior to the proposed time of administration.~10. Any history or presence of serious illness, bleeding disorders or autoimmune disorders, or planned surgeries.~11. Weight less than 50 kg (110 pounds)~12. History of hepatitis or liver disease.~13. Subjects receiving immunosuppressive therapy.~14. Presence of HLA DQB1\*06:02, the narcolepsy risk associated allele.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- AS03 adjuvanted (Type: EXPERIMENTAL): Adminsitered day 1, booster at Day 21
- unadjuvanted (Type: EXPERIMENTAL): Administer day 1 and booster at Day 21

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* New diagnosis of eosinophilic esophagitis (per 2007 consensus guidelines)~Exclusion Criteria:~* Age \< 18~* Inability to read or understand English~* Pregnant or nursing women~* Previous allergic reactions to steroid medications~* Current use of systemic steroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- inhaled/swallowed budesonide (Type: EXPERIMENTAL): None
- viscous/swallowed budesonide (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combined Corticosteroid With Low Volume Compared to High Volume in Impingement Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. participants with clinically diagnosed the rotator cuff impingement~2. participants aged 20 years and older~3. at least 1 month's duration~4. pain of moderate to severe intensity, defined as a score of 5 or more points on a 10-cm visual analog scale (VAS) rated from 0 (no pain) to 10 (worst imaginable pain)~Exclusion Criteria:~1. patients with adhesive capsulitis of the shoulder (normal radiograph of affected shoulder, and restriction of passive motion \>30° in ≥2 planes of movement)~2. previous trauma history at currently affected shoulder~3. previous corticosteroid injection history at the affected shoulder~4. abnormal calcification and/or primary osteoarthritis of the shoulder joint on plain radiographs~5. use of medication such as antiplatelet agent or anticoagulation.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lidocaine 3 cc & Triamcinolone Acetonide (Type: EXPERIMENTAL): None
- Lidocaine 9cc & Triamcinolone Acetonide (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of open angle glaucoma or ocular hypertension~Exclusion Criteria:~* Uncontrolled medical conditions~* Anticipated wearing of contact lenses during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bimatoprost 20 µg generation 2, bimatoprost 0.03% (Type: OTHER): Single dose of bimatoprost ophthalmic 20 µg generation 2 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
- bimatoprost 15 µg generation 2, bimatoprost 0.03% (Type: OTHER): Single dose of bimatoprost ophthalmic 15 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
- bimatoprost 10 µg generation 2, bimatoprost 0.03% (Type: OTHER): Single dose of bimatoprost ophthalmic 10 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
- bimatoprost 6 µg generation 2, bimatoprost 0.03% (Type: OTHER): Single dose of bimatoprost ophthalmic 6 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
- bimatoprost 15 µg generation 1, bimatoprost 0.03% (Type: OTHER): Single dose of bimatoprost ophthalmic 15 µg generation 1 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
- bimatoprost 10 µg generation 1, bimatoprost 0.03% (Type: OTHER): Single dose of bimatoprost ophthalmic 10 µg generation 1 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Escitalopram in Adult Patients With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must meet Diagnostic and Statistical Manual, Fourth Edition (DSM-IV) diagnostic criteria for Major Depressive Disorder.~* The patient's current depressive episode must be at least 12 weeks in duration.~Exclusion Criteria:~* Women who are pregnant, women who will be breastfeeding during the study, and women of childbearing potential who are not practicing a reliable method of birth control.~* Patients who currently meet DSM-IV criteria for: a. bipolar disorder; b. schizophrenia or any psychotic disorder; c. obsessive-compulsive disorder; d. mental retardation or any pervasive developmental disorder or cognitive disorder.~* Patients who are considered a suicide risk.~* Patients with a history of seizure disorder, or any history of seizure, stroke, significant head injury, or any other condition that predisposes toward risk of seizure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic or cytologic diagnosis of urothelial (transitional cell) carcinoma with the exception of micropapillary subtype~* Patients must have recurrent disease (locally advanced or metastatic) that is not amenable to local therapy or newly diagnosed distant metastatic disease~* Measurable disease defined by RECIST v.1.0~* ECOG performance status of 2 or better~* Adequate organ and bone marrow function defined as~Exclusion Criteria:~* Other tumor type than urothelial carcinoma~* Presence or history of CNS metastasis~* Prior systemic chemotherapy or immunotherapy (but prior local intravesical chemotherapy or immunotherapy was allowed. And recurrent disease after adjuvant or neoadjuvant cisplatin-based systemic chemotherapy is allowed if the last chemotherapy was administered 1 year or more before the patient enrollment.)~* Presence of second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin)~* Peripheral sensory neuropathy grade 2 or worse~* Other serious illness or medical conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- PemCis (Type: EXPERIMENTAL): Pemetrexed plus Cisplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Irbesartan on Insulin Sensitivity in Chronic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. ambulatory patients with symptomatic chronic heart failure (NAHY II-IV)~2. ischemic etiology~3. LVEF ≤ 45%~4. standard medical treatment for CHF (such as diuretics, beta blockers, ACE inhibitors, aspirin or warfarin). Patients should be treated with ACI inhibitor for at least 12 months prior to enrolment into the study. Patients should not be treated with angiotensin II receptor antagonists during the study other than the trial medication. Further medical treatment such as spironolactone, amiodarone and others are allowed if the patient is on a stable dose at the beginning of the trial. Dosages should be kept stable during the trial except adjustment is judged necessary for clinical reason.~5. Patient should be hospitalised due to deterioration of the cardiac disease at least once in the last 12 months under ACE-I therapy.~6. age \> 21 years~7. informed consent~Exclusion Criteria:~1. hospitalisation with intervention within 2 weeks of intended randomisation~2. unstable IHD or Myocardial infarction \< 2 months~3. open diagnosed diabetes mellitus / antidiabetic treatment with insulin, metformin, sulfonylurea, glinides~4. COPD treated with steroids

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Type 1 Diabetes Mellitus (T1DM) for at least 2 years and receiving daily insulin since the time of diagnosis~Exclusion Criteria:~* Have a history of hypersensitivity to glucagon or any related products or severe hypersensitivity reactions (such as angioedema) to any drugs~* Have a history of pheochromocytoma (that is, adrenal gland tumor) or insulinoma~* Occurrence of an episode of severe hypoglycemia (defined as requiring the assistance of another person in the 1 month prior to enrolling in the study)~* Have a history of epilepsy or seizure disorder~* Are women who are pregnant or lactating~* Have, except for the current regimen of insulin therapy and concomitant medication, regular use of or intended use of any over-the-counter or prescription medications or nutritional supplements that treat hyperglycemia or insulin resistance or that promote weight loss within 14 days before dosing~* Daily use of systemic beta-blocker, indomethacin, warfarin or anticholinergic drugs~* Require daily insulin treatment greater than (\>)1.5 unit/kilograms (U/kg)/body weight

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Nasal Glucagon (Type: EXPERIMENTAL): Single dose of Nasal Glucagon.
- Intramuscular Glucagon (Type: ACTIVE_COMPARATOR): Single intramuscular (IM) dose of Glucagon.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PGL4001 Versus GnRH-agonist in Uterine Myomas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Be a pre-menopausal woman between 18 and 50 years inclusive.~* Have excessive uterine bleeding due to myoma~* Have a myomatous uterus with at least one myoma of ≥ 3 cm diameter in size~* Be eligible for one surgical procedure: e.g. hysterectomy, myomectomy or others.~* If of childbearing potential the subject must be practicing a non-hormonal method of contraception.~* Have a Body Mass Index (BMI) ≥ 18 and ≤ 40.~Exclusion Criteria:~* Has a history of or current uterine, cervical, ovarian or breast cancer.~* Has a history of or current endometrium atypical hyperplasia or adenocarcinoma.~* Has a known severe coagulation disorder.~* Has a history of or current treatment for myoma with a Selective Progesterone Receptor Modulator (SPRM) or a GnRH-agonist.~* Has a history of or known current osteoporosis.~* Has abnormal hepatic function at study entry.~* Has a positive pregnancy test at baseline or is nursing or planning a pregnancy during the course of the study.~* Has a current (within twelve months) problem with alcohol or drug abuse.~* Is currently enrolled in an investigational drug or device study or has participated in such a study within the last 30 days.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- A (PGL4001 5 mg) (Type: EXPERIMENTAL): Drug: PGL4001 5mg (oral tablets) and leuproreline matching placebo (intramuscular injection)
- B (PGL4001 10mg) (Type: EXPERIMENTAL): Drug: PGL4001 10 mg (oral tablets) and leuproreline matching placebo (intramuscular injection)
- C (GnRH-agonist) (Type: ACTIVE_COMPARATOR): PGL4001 matching placebo (oral tablets) and leuprorelin 3.75 mg (intramuscular injection)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimising Operational Use of Artemether-lumefantrine Comparing 3 Day Versus 5 Day

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 6 year~2. Symptomatic malaria infection, i.e. history of fever or presence of fever \>37.5°C~3. Microscopic confirmation of asexual stages of P. falciparum (may be mixed with non-falciparum species) with parasitaemia PFT≥5/500 WBC~4. Written informed consent given to participate in the trial~Exclusion Criteria:~1. Pregnancy or lactation (urine test for β HCG to be performed on any woman of child bearing age unless menstruating).~2. Female of 12 to 18 years of age~3. P. falciparum asexual stage parasitaemia greater than or equal to 4% red blood cells (175,000/µL).~4. Signs or symptoms indicative of severe malaria including:~   * Impaired consciousness (Blantyre Coma Score \<5 or Glasgow Coma Scale \<15)~  * Severe anaemia (Hb% \<5 mg/dl)~  * Bleeding disorder -evidenced by epistaxis, bleeding gums, frank haematuria, bleeding from venepuncture sites~  * Respiratory distress~  * Severe jaundice~  * Haemodynamic shock~5. A full course of artemether-lumefantrine treatment in the previous 28 days~6. Known hypersensitivity to artemisinins - defined as history of erythroderma/other severe cutaneous reaction, angioedema or anaphylaxis~7. History of splenectomy

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AL3days (Type: ACTIVE_COMPARATOR): Artemether-lumefantrine 3 days
- AL5days (Type: EXPERIMENTAL): Artemether-lumefantrine 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Subunit Plague Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults aged 18-55months old as established by medical history and clinical examination.~* The subjects' guardians are able to understand and sign the informed consent.~* Subjects who can and will comply with the requirements of the protocol.~* Subjects with temperature ≤37.0°C on axillary setting.~Exclusion Criteria:~* Family history of seizures or progressive neurological disease.~* Subject who has a medical history of plague, or had been vaccination of plague vaccine.~* Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine.~* Any confirmed or suspected autoimmune diseases or immune deficiency disorders, including human immunodeficiency virus (HIV) infection.~* Dysgenopathy or severe chronic disease.~* Pregnant or lactating women.~* Women of reproductive age without contraception.~* Thrombocytopenia or other blood coagulation disorder, may cause taboo of intramuscular injection.~* Any prior administration of immunodepressant or corticosteroids, and antianaphylactic treatment, cytotoxic therapy in last 6 months.~* Difficult to collecting blood sample.~* Any prior administration of blood products in last 3 month.~* Any prior administration of other research medicines in last 1 month.~* Any prior administration of attenuated live vaccine in last 4 weeks.~* Any prior administration of subunit or inactivated vaccines in last 2 weeks.~* Had fever before vaccination, subjects with temperature \>37.0°C on axillary setting.~* Rash on the injection site that may affect safety observation.~* Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives.~Exclusion Criteria for the second dose:~* Subject who must be excluded according to the exclusion criteria for the first dose.~* Any serious adverse events caused by vaccination.~* Hypersensitivity after vaccination (include urticarial or rash in 30 minutes after vaccination).Hypersensitivity after vaccination (include urticarial or rash in 30 minutes after vaccination).~* Other adverse reactions in the opinion of the investigator that affect continue vaccination (include: severely serious symptom of pain, swelling, Limitation of motion, continuous high fever, headache and other Systemic or local reactions).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 15µg vaccine (Type: EXPERIMENTAL): 15µg plague vaccine of 1.0ml in 120 adults aged 18-55 years old at day 0 and 28.
- 30µg vaccine (Type: EXPERIMENTAL): 30µg plague vaccine of 1.0ml in 120 adults aged 18-55 years old at day 0 and 28.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who have completed all four treatment regimens in the core study CSOM230B2201 (NCT00088582) and achieved biochemical control in growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels after at least one month of pasireotide administration at any of the three doses.~* Participants who did not experience any unacceptable adverse events or tolerability issues during the core study CSOM230B2201.~Exclusion Criteria:~* Participants who experienced or developed compression of the optic chiasm causing any visual field defect during the core study CSOM230B2201.~* Participants who required a surgical intervention for relief of any sign or symptom associated with tumor compression during the core study CSOM230B2201.~* Participants who experienced or developed congestive heart failure, unstable angina, sustained ventricular tachycardia, ventricular fibrillation or acute myocardial infraction during the core study CSOM230B2201.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Pasireotide s.c. Overall (Type: EXPERIMENTAL): Participants received pasireotide as a daily subcutaneous (s.c) injection, every 12 hours at 9:00 AM and 9:00 PM at the dose at which the biochemical control was achieved (either 200, 400, or 600 microgram (μg)) for as long as the participant benefited from the treatment, and there were no safety or tolerability concerns (median duration of 22.7 months).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete